CN101353306B - Refining method of salvianolic acid A - Google Patents
Refining method of salvianolic acid A Download PDFInfo
- Publication number
- CN101353306B CN101353306B CN2008101207846A CN200810120784A CN101353306B CN 101353306 B CN101353306 B CN 101353306B CN 2008101207846 A CN2008101207846 A CN 2008101207846A CN 200810120784 A CN200810120784 A CN 200810120784A CN 101353306 B CN101353306 B CN 101353306B
- Authority
- CN
- China
- Prior art keywords
- salvianolic acid
- acid
- organic solvent
- purification
- extraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 title claims abstract description 54
- YMGFTDKNIWPMGF-AGYDPFETSA-N 3-(3,4-dihydroxyphenyl)-2-[(e)-3-[2-[(e)-2-(3,4-dihydroxyphenyl)ethenyl]-3,4-dihydroxyphenyl]prop-2-enoyl]oxypropanoic acid Chemical compound C=1C=C(O)C(O)=C(\C=C\C=2C=C(O)C(O)=CC=2)C=1/C=C/C(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-AGYDPFETSA-N 0.000 title claims abstract description 51
- 238000000034 method Methods 0.000 title claims abstract description 27
- 238000007670 refining Methods 0.000 title description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 38
- 239000003960 organic solvent Substances 0.000 claims abstract description 29
- 238000000746 purification Methods 0.000 claims abstract description 21
- 239000000284 extract Substances 0.000 claims abstract description 19
- 239000002253 acid Substances 0.000 claims abstract description 18
- 239000012074 organic phase Substances 0.000 claims abstract description 11
- 238000000638 solvent extraction Methods 0.000 claims abstract description 11
- 239000012535 impurity Substances 0.000 claims abstract description 8
- 240000007164 Salvia officinalis Species 0.000 claims description 23
- 235000005412 red sage Nutrition 0.000 claims description 17
- 238000000605 extraction Methods 0.000 claims description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 7
- 239000011707 mineral Substances 0.000 claims description 7
- 235000017276 Salvia Nutrition 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 238000003809 water extraction Methods 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 claims description 4
- 239000012071 phase Substances 0.000 claims description 4
- 229940090181 propyl acetate Drugs 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 4
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 3
- 229940043232 butyl acetate Drugs 0.000 claims description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 3
- 229940093499 ethyl acetate Drugs 0.000 claims description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 claims 3
- 238000011084 recovery Methods 0.000 abstract description 13
- 239000000287 crude extract Substances 0.000 abstract description 7
- 238000002360 preparation method Methods 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 4
- 238000009776 industrial production Methods 0.000 abstract description 2
- 238000000622 liquid--liquid extraction Methods 0.000 abstract description 2
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- YMGFTDKNIWPMGF-UCPJVGPRSA-N Salvianolic acid A Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-UCPJVGPRSA-N 0.000 description 3
- 229930183842 salvianolic acid Natural products 0.000 description 3
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000011260 aqueous acid Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000008899 fufang danshen Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- XQJMXPAEFMWDOZ-UHFFFAOYSA-N 3exo-benzoyloxy-tropane Natural products CN1C(C2)CCC1CC2OC(=O)C1=CC=CC=C1 XQJMXPAEFMWDOZ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- QQXLDOJGLXJCSE-UHFFFAOYSA-N N-methylnortropinone Natural products C1C(=O)CC2CCC1N2C QQXLDOJGLXJCSE-UHFFFAOYSA-N 0.000 description 1
- QIZDQFOVGFDBKW-DHBOJHSNSA-N Pseudotropine Natural products OC1C[C@@H]2[N+](C)[C@H](C1)CC2 QIZDQFOVGFDBKW-DHBOJHSNSA-N 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000013094 purity test Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- ZMMKVDBZTXUHFO-DDWIOCJRSA-M sodium;(2r)-3-(3,4-dihydroxyphenyl)-2-hydroxypropanoate Chemical compound [Na+].[O-]C(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 ZMMKVDBZTXUHFO-DDWIOCJRSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- CYHOMWAPJJPNMW-JIGDXULJSA-N tropine Chemical compound C1[C@@H](O)C[C@H]2CC[C@@H]1N2C CYHOMWAPJJPNMW-JIGDXULJSA-N 0.000 description 1
- 239000008886 xiangdan Substances 0.000 description 1
Images
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a purification method of a salvianolic acid A. A salvia miltiorrhiza water extract is extracted by an organic solvent extraction method to obtain a crude extract of the salvianolic acid A, the crude extract is extracted by acid water to remove impurities, and the crude extract without the impurity is condensed and dried by an organic phase to obtain the high-purity salvianolic acid A. The purification method of the invention has more than 95% purification recovery rate and more than 90% purity of the salvianolic acid A (calculated based on medicinal material weight and the yield is more than 0.3%). The most important point is that the main purification process of the method is of a liquid-liquid extraction, which simplifies the process and the required equipment, and the method is suitable for large-scale industrial production. The purification method has the advantages of reasonable design, high fine purification recovery rate, good purity, stable performance, simple preparation process and low production cost.
Description
Technical field
The invention belongs to the purification of tcm method, relate generally to a kind of process for purification of Chinese medicine salvianolic acid A.
Background technology
The red sage root is one of the most frequently used Chinese medicine medicinal material.Be used for the treatment of cardiovascular and cerebrovascular diseases such as stenocardia, hypertension, coronary heart disease and apoplexy.The Chinese medicine preparation that is used as medicine with salvia piece or red sage root crude extract has a lot, as FUFANG DANSHEN PIAN, FUFANG DANSHEN DIWAN, Radix Salviae Miltiorrhizae Injection, XIANGDAN ZHUSHEYE etc., the preparation that also has utilization to separate from the red sage root in addition to obtain pure compound or its esters to make is as Sodium Danshensu injection liquid, salvianolic acid B injection etc.
In recent years, along with going deep into of pharmacological research, the multiple pharmacologically active of salvianolic acid A is found.Has anti-tumor activity as discovery salvianolic acid As such as Zhen Yongsu; Discovery salvianolic acid As such as Du Guanhua have significant protective effect to the isolated rat myocardial ischemia-reperfusion injury, the brain injury that the mouse brain ischemia-reperfusion is caused has provide protection, and the mouse memory acquired disturbance that Daturamine or winter tropine are caused improves significantly etc.; Inscription on pottery discovery salvianolic acid As such as (Tao Wen) has provide protection to the rats'liver damage that tetracol phenixin causes.Li Zhigangs etc. have also been developed the red sage root salvianolic acid A tablet and the injection of treatment cardiovascular disorder.
The relevant patent of the preparation salvianolic acid A of having applied for more (seeing Table 1) all comprise the separation method (chromatographic separation and solvent extraction, protein adsorption and solvent extraction) of two or more different principle, thereby processing step is more, needs multiple plant and instrument.
The comparison of table 1. patent applied for.
Patent publication No. | Principle and step | Yield | Purity |
CN1830947A | Water or alcohol extracting, concentrated back high-temperature high-voltage reaction, column chromatography, adjusting pH value, organic solvent extraction | More than 0.35% | More than 80% |
CN1887849 | Water or alcohol extracting, column chromatography are regulated pH value, organic solvent extraction | More than 0.3% | More than 90% |
CN101041620 | Water or alcohol extracting, column chromatography are regulated pH value, organic solvent extraction | — | 90% |
CN101230003 | Water or alcohol extracting, acid adjustment, thermal conversion, resin column chromatography | 1%-2% | — |
CN101130498 | Water or alcohol extracting, protein adsorption, parsing, organic solvent extraction | 0.3% | More than 90% |
Because salvianolic acid A content in medicinal material is very low, processing step is many more, and the process loss is big more.In addition, column chromatography uses in the big production of industry certain limitation, can not satisfy the needs of industrial production salvianolic acid A preparation well.
Summary of the invention
The present invention is directed to the deficiency that above-mentioned prior art exists, a kind of process for purification of salvianolic acid A is provided, be achieved through the following technical solutions: the organic phase that adopt organic solvent extractionprocess extraction red sage root water extract to obtain salvianolic acid A crude extract (organic phase), to adopt the sour water extraction process to remove impurity, contains refining salvianolic acid A through concentrate, dry after acquisition pale yellow powder, i.e. high-purity danshinolic acid A.Be specifically related to following steps:
1, abstraction purification
Adopt the salvianolic acid A in the organic solvent extraction enrichment red sage root water extract, through the sour water removal impurity of repeatedly stripping, obtain highly purified salvianolic acid A again.
(1) gets red sage root water extract to be extracted, add organic solvent and extract, separate the organic solvent layer that contains salvianolic acid A.
(2) get the organic solvent layer that contains salvianolic acid A and directly or after concentrating repeatedly extract removal impurity, separate the organic solvent layer that contains refining salvianolic acid A with sour water.
Wherein the extracting mode such as adopt that normal reflux, temperature are soaked of the red sage root water extract in the step (1) extracts from red rooted salvia and obtains.Used organic solvent is acetate esters solvents such as ethyl acetate, propyl acetate, butylacetate, and extraction times is 2~10 times.The organic solvent amount that is used to extract is 1~5 times of red sage root water liquid-extracting amount.
In the step (2) to regulate the acid of sour water pH value be mineral acid, sour water pH value scope is 1~5, extraction times is 3~10 times.
2, concentrate drying
Concentrate and adopt concentrating under reduced pressure or normal pressure to concentrate, dry employing vacuum-drying or lyophilize.
Salvianolic acid A purification process of the present invention, utilize the polarity character littler of salvianolic acid A, rancinamycin IV than the polarity of Salvianic acidA, salvianolic acid B, adopt organic solvent extracting and enriching under pH4~6 conditions mainly to be contained the salvianolic acid A crude extract of salvianolic acid A and rancinamycin IV, utilize under salvianolic acid A and the rancinamycin IV acidic conditions the different of in water solubleness again, through the sour water removal rancinamycin IV of repeatedly stripping, obtain highly purified salvianolic acid A, thereby reach the purpose of separation and purification salvianolic acid A.This method purifying rate of recovery reaches more than 95%%, the purity of salvianolic acid A reaches (in medicinal material weight, yield is more than 0.3%) more than 90%, and most importantly main means of purification only is liquid-liquid extraction in this technology, thereby make technology and required equipment more simple, be fit to the big production of industry.This method makes with extra care that rate of recovery height, purity are good, stable performance, technology is simple, production cost is low process for purification
Description of drawings
Fig. 1 salvianolic acid A crude extract HPLC color atlas.
Fig. 2 salvianolic acid A purity test color atlas.
Specific embodiments
Embodiment 1: the extracting and purifying method of salvianolic acid A the steps include:
1. get salvia piece 100g, add 1L water, refluxing extraction 2 hours is filtered, filter residue adds 0.8L water again, and refluxing extraction 1.5 hours is filtered, and merges filtrate twice, 70 ℃ are evaporated to about 50mL, use equal volume of ethyl acetate 3 times, merge organic phase, are concentrated into 1/3 volume;
2. to regulate water pH value be 1 to hydrochloric acid, with spissated organic extractant phase in the step 15 times, casts out water, and the concentrating under reduced pressure organic phase is to the medicinal extract shape, and lyophilize gets pale yellow powder, is salvianolic acid A.Its purity is 92%, and the rate of recovery is 97%.
The result is referring to Fig. 1 and Fig. 2, and peak A is a salvianolic acid A among the figure.
Embodiment 2: removing extraction solvent is propyl acetate, and the propyl acetate amount of adding is that all the other steps are identical with embodiment 1 outside 3 times of amounts of red sage root water extract.Its purity is 93%, and the rate of recovery is 95%.
Embodiment 3: removing extraction solvent is butylacetate, and extraction times is outside 5 times, and all the other steps are identical with embodiment 1.Its purity is 93%, and the rate of recovery is 95%.
Embodiment 4: except that used aqueous acid pH value in the step 2 is 2, (50 ℃, vacuum tightness-0.09MPa), all the other steps are identical with embodiment 1 in dry employing vacuum-drying.Its purity is 95%, and the rate of recovery is 95%.
Embodiment 5: except that used aqueous acid pH value in the step 2 is 3, all the other steps are identical with embodiment 1.Its purity is 91%, and the rate of recovery is 96%.
Embodiment 6: be 7 times except that sour water extraction times in the step 2, all the other steps are identical with embodiment 1.Its purity is 94%, and the rate of recovery is 95%.
Embodiment 7: except that sour water extraction times in the step 2 is 10 times, all the other steps are identical with embodiment 1.Its purity is 96%, and the rate of recovery is 95%.
Embodiment 8: except that used mineral acid in the step 2 is the sulfuric acid, all the other steps are identical with embodiment 1.Its purity is 92%, and the rate of recovery is 95%.
Embodiment 9: except that used mineral acid in the step 2 is a phosphoric acid, sour water pH value is outside 4, and all the other steps are identical with embodiment 1.Its purity is 90%, and the rate of recovery is 95%.
Claims (6)
1. the process for purification of a salvianolic acid A, it is characterized in that realizing by following steps: the extracting mode that (1) adopts normal reflux mode or temperature to soak extracts red sage root water extract from red rooted salvia, with the salvianolic acid A in the organic solvent extractionprocess extraction red sage root water extract, separate and contain the organic solvent layer of salvianolic acid A as organic phase, adopt the sour water extraction process to remove impurity, acquisition contains the organic solvent phase of salvianolic acid A, the pH value of used sour water is 1~5, (2) will contain the organic phase of salvianolic acid A through concentrating under reduced pressure, obtain pale yellow powder after the vacuum-drying, be high-purity danshinolic acid A, the used organic solvent of step (1) is the acetate esters solvent, and regulating the used acid of sour water pH in the step (1) is mineral acid.
2. the process for purification of a kind of salvianolic acid A according to claim 1, it is characterized in that: the described organic solvent extraction number of times of step (1) is 2~10 times, the organic solvent amount that is used to extract is 1~5 times of red sage root water liquid-extracting amount.
3. the process for purification of a kind of salvianolic acid A according to claim 1, it is characterized in that: extracting used organic solvent is ethyl acetate, propyl acetate or butylacetate.
4. the process for purification of a kind of salvianolic acid A according to claim 1 is characterized in that: regulating the used acid of sour water pH in the step (1) is mineral acid, and extraction times is 3~10 times.
5. the process for purification of a salvianolic acid A, it is characterized in that realizing by following steps: the extracting mode that (1) adopts normal reflux mode or temperature to soak extracts red sage root water extract from red rooted salvia, with the salvianolic acid A in the organic solvent extractionprocess extraction red sage root water extract, separate and contain the organic solvent layer of salvianolic acid A as organic phase, adopt the sour water extraction process to remove impurity, acquisition contains the organic solvent phase of salvianolic acid A, the pH value of used sour water is 1~5, (2) organic phase that will contain salvianolic acid A concentrates through normal pressure, obtain pale yellow powder after the vacuum-drying, be high-purity danshinolic acid A, the used organic solvent of step (1) is the acetate esters solvent, and regulating the used acid of sour water pH in the step (1) is mineral acid.
6. the process for purification of a salvianolic acid A, it is characterized in that realizing by following steps: the extracting mode that (1) adopts normal reflux mode or temperature to soak extracts red sage root water extract from red rooted salvia, with the salvianolic acid A in the organic solvent extractionprocess extraction red sage root water extract, separate and contain the organic solvent layer of salvianolic acid A as organic phase, adopt the sour water extraction process to remove impurity, acquisition contains the organic solvent phase of salvianolic acid A, the pH value of used sour water is 1~5, (2) will contain the organic phase of salvianolic acid A through concentrating under reduced pressure, obtain pale yellow powder after the lyophilize, be high-purity danshinolic acid A, the used organic solvent of step (1) is the acetate esters solvent, and regulating the used acid of sour water pH in the step (1) is mineral acid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101207846A CN101353306B (en) | 2008-09-05 | 2008-09-05 | Refining method of salvianolic acid A |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101207846A CN101353306B (en) | 2008-09-05 | 2008-09-05 | Refining method of salvianolic acid A |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101353306A CN101353306A (en) | 2009-01-28 |
CN101353306B true CN101353306B (en) | 2011-05-18 |
Family
ID=40306357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008101207846A Expired - Fee Related CN101353306B (en) | 2008-09-05 | 2008-09-05 | Refining method of salvianolic acid A |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101353306B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102993015B (en) * | 2012-11-20 | 2015-04-08 | 江西青峰药业有限公司 | Method for purifying salvianolic acid A |
CN103044251B (en) * | 2012-11-20 | 2015-01-07 | 江西青峰药业有限公司 | Method for preparing salvianolic acid A |
CN107032996B (en) * | 2017-05-12 | 2019-07-09 | 浙江大学 | Method that is a kind of while refining salviandic acid A and protocatechualdehyde |
CN109748793B (en) * | 2018-12-29 | 2021-07-09 | 正大青春宝药业有限公司 | Method for removing isosalvianolic acid A1 and isosalvianolic acid A2 from sodium salvianolic acid A |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1887849A (en) * | 2006-07-13 | 2007-01-03 | 正大青春宝药业有限公司 | Salvianolic acid A preparing process |
CN101130498A (en) * | 2007-08-24 | 2008-02-27 | 浙江大学 | Method for extracting and purifying salvianolic acid A |
-
2008
- 2008-09-05 CN CN2008101207846A patent/CN101353306B/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1887849A (en) * | 2006-07-13 | 2007-01-03 | 正大青春宝药业有限公司 | Salvianolic acid A preparing process |
CN101130498A (en) * | 2007-08-24 | 2008-02-27 | 浙江大学 | Method for extracting and purifying salvianolic acid A |
Non-Patent Citations (1)
Title |
---|
刘重芳等.丹参不同提取工艺比较.中成药.1999,21(8),385-388. * |
Also Published As
Publication number | Publication date |
---|---|
CN101353306A (en) | 2009-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101830849B (en) | Method for preparing simplified high-purity bulleyaconitine A | |
CN101012163B (en) | Method of preparing high purity Danshensu | |
CN102408314B (en) | Method for preparing high-purity magnolol and magnolol | |
CN105481711B (en) | Hydroxy-beta-sanshool monomer preparation method | |
CN101812100A (en) | Method for preparing icariin | |
CN102001947A (en) | Method for preparing honeysuckle chlorogenic acid | |
CN101353306B (en) | Refining method of salvianolic acid A | |
CN104784254A (en) | Extraction method for producing baicalin with biological enzyme method | |
CN101348474A (en) | Method for preparing salvianolic acid B and tanshinol from Salvia miltiorrhiza stem | |
CN100567249C (en) | The preparation method of danshen root salvianolic acid A | |
CN1887849A (en) | Salvianolic acid A preparing process | |
CN103012518B (en) | Production process for simultaneously extracting asperuloside and chlorogenic acid from folium cortex eucommiae | |
CN108117571B (en) | Preparation method of gentiopicroside monomer | |
CN102250164A (en) | Purification method of gastrodin | |
CN101260133B (en) | Method for preparing hyperoside and isoquercetin from cotton petal | |
CN103145548B (en) | Method for rapidly separating and purifying tanshinol in salvia miltiorrhiza medicinal materials | |
CN101130498B (en) | Method for extracting and purifying salvianolic acid A | |
CN102391330A (en) | Method for extracting liquiritin from liquorice | |
CN102432420A (en) | Method for extracting and separating beta-elemene from Lantana camara | |
CN102391232B (en) | The method of Liquiritigenin is extracted from Radix Glycyrrhizae | |
CN101891729A (en) | Method for extracting high-purity rhamnazin from ford nervilia leaf | |
CN103864767A (en) | Puerarin refining process | |
CN102826997A (en) | Method for extracting 1'-acetoxychavicol acetate from fructus galangae | |
CN101786984B (en) | Method for extracting liensinine, isoliensinine and neferine from lotus plumule | |
CN103242161B (en) | Method for preparing salvianolic acid A |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110518 Termination date: 20150905 |
|
EXPY | Termination of patent right or utility model |